Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2430-2438

  Matthews, Connie P ^a   Birkholz, Alysia M ^a   Baker, Alyson R ^a   Perella, Christine M ^b   Beck Jr , George R ^c   Young, Matthew R ^a   Colburn, Nancy H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; CYCLOOXYGENASE 2; DIMETHYLBENZ[A]ANTHRACENE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPONTIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN C JUN; PROTEIN E7; PROTEIN FOS; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA; TUMOR PROMOTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; HUMAN PAPILLOMAVIRUS TYPE 16; HYPERPLASIA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SKIN CARCINOGENESIS; TRANSGENIC MOUSE; TUMOR PROMOTION; UPREGULATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, TRANSGENIC; NF-KAPPA B; ONCOGENE PROTEINS, VIRAL; OSTEOPONTIN; PEPTIDE FRAGMENTS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-JUN; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 34047264014     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0522     Document Type: Article

References (46)

1. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A 2005;102:2490-5.
2. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003;63:4862-71.
3. Song S, Liem A, Miller JA, Lambert PF. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 2000;267:141-50.
4. Bernstein LR, Colburn NH. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 1989;244:566-9.
5. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 1994;91:609-13.
6. Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH. Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchor-age independent growth of HPV immortalized human keratinocytes. Oncogene 1998;16:2711-21.
7. Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA 1999;96:9827-32.
8. Li JJ, Cao Y, Young MR, Colburn NH. Induced expression of dominant-negative c-Jun down-regulates NFκB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes. Mol Carcinog 2000; 29:159-69.
9. Young MR, Farrell L, Lambert P, Awasthi P, Colburn NH. Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-Jun. Mol Carcinog 2002;34:72-7.
10. Domann FE, Levy JP, Birrer MJ, Bowden GT. Stable expression of a c-Jun deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ 1994;5:9-16.
11. Hennigan RF, Hawker KL, Ozanne BW. Fos-transformation activates genes associated with invasion. Oncogene 1994;9:3591-600.
12. Lamb RF, Hennigan RF, Turnbull K, et al. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 1997;17:963-76.
13. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
14. Hilberg F, Aguzzi A, Howells N, Wagner EF. c-Jun is essential for normal mouse development and hepatogenesis. Nature 1993;365:179-81.
15. Johnson RS, van Lingen B, Papaioannou VE, Spiegelman BM. A null mutation at the c-Jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev 1993;7:1309-17.
16. Zenz R, Wagner EF. Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol 2006;38:1043-9.
17. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-Jun Oncogene 1993;8:877-86.
18. Dong Z, Crawford HC, Lavrovsky V, et al. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog 1997;19:204-12.
19. Nair S, Pillai MR. Human papillomavirus and disease mechanisms: relevance to oral and cervical cancers. Oral Dis 2005;11:350-9.
20. Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G. The NF-κB-mediated control of ROS and JNK signaling. Histol Histopathol 2006;21:69-80.
21. Beauparlant P, Kwan I, Bitar R, et al. Disruption of Iκ Bα regulation by antisense RNA expression leads to malignant transformation. Oncogene 1994;9:3189-97.
22. Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X, Nerenberg M. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 1992;258:1792-5.
23. Greten FR, Karin M. The IKK/NF-κB activation pathway - a target for prevention and treatment of cancer. Cancer Lett 2004;206:193-9.
24. Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 1996;70:1873-81.
25. Rho O, Bol DK, You J, Beltran L, Rupp T, DiGiovanni J. Altered expression of insulin-like growth factor I and its receptor during multistage carcinogenesis in mouse skin. Mol Carcinog 1996;17:62-9.
26. Kim Y, Fischer SM. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues. J Biol Chem 1998;273:27686-94.
27. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, Yuspa SH. Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol 1995;254:3-20.
28. Yang HS, Jansen AP, Nair R, et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation. Oncogene 2001;20:669-76.
29. Avis I, Martinez A, Tauler J, et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 2005;65: 4181-90.
30. Chang PL, Cao M, Hicks P. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis 2003;24: 1749-58.
31. Rao JS, Gondi C, Chetty C, et al. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 2005;4:1399-408.
32. Nozaki S, Endo Y, Nakahara H, et al. Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. Oral Oncol 2005;41:971-7.
33. Barcelos LS, Talvani A, Teixeira AS, Cassali GD, Andrade SP, Teixeira MM. Production and in vivo effects of chemokines CXCL1-3/KC and CCL2/JE in a model of inflammatory angiogenesis in mice. Inflamm Res 2004; 53:576-84.
34. Leaner VD, Kinoshita I, Birrer MJ. AP-1 complexes containing c-Jun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets. Oncogene 2003;22:5619-29.
35. Kinoshita I, Leaner V, Katabami M, et al. Identification of c-Jun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for c-Jun-mediated anchorage-independent growth. Oncogene 2003;22:2710-22.
36. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neupositive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18649-57.
37. Rebollo A, Dumoutier L, Renauld JC, Zaballos A, Ayllon V, Martinez AC. Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. Mol Cell Biol 2000;20:3407-16.
38. Foster LC, Wiesel P, Huggins GS, et al. Role of activating protein-1 and high mobility group-I (Y) protein in the induction of CD44 gene expression by interleukin-1β in vascular smooth muscle cells. FASEB J 2000;14:368-78.
39. Williams TM, Lee H, Cheung MW, et al. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Biol Chem 2004;279:24745-56.
40. Egan JE, Hall AB, Yatsula BA Bar-Sagi D. The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc Natl Acad Sci U S A 2002;99:6041-6.
41. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004;68:1089-100.
42. 2 promotes angiogenesis in colorectal cancer. J Exp Med 2006;203:941-51.
43. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
44. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005;65:10637-41.
45. Mann JR, Backhand MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005;2:202-10.
46. Young MR, Nair R, Bucheimer N, et al. Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol Cell Biol 2002;22:587-98.